Tokyo Tape
Sign in
← Vital Ksk Holdings

Quarterly report · Q3

3151.TEDINET S100SUKH
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥448.9bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥581.3bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥444.4bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥5.7bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥3.1bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥6.5bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥6.0bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥7.6bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥4.1bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥5.1bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥5.1bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥2.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥328.3bnat 2023-12-31Cons.Assets
Total assets¥297.3bnat 2023-03-31Cons.Assets
Total assets¥336.1bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥225.6bnat 2023-12-31Cons.Liabilities
Total liabilities¥197.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥102.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥100.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥102.4bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥31.1bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥19.0bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥99.122023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥53.662023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥92.692022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.592022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥19.222022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.9%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.3%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio30.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-12-31¥2.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-12-31¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-12-31−¥162m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥10.0bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31¥61m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2023-04-01 → 2023-12-31¥431.3bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2023-04-01 → 2023-12-31¥423.2bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2023-04-01 → 2023-12-31¥5.2bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥14.3bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥14.3bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥9m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥259m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥8.5bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥8.5bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥288m
—segment totalrevenue2023-04-01 → 2023-12-31¥454.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥446.0bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥8.0bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥5.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-12-31¥458.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-12-31¥448.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-12-31¥10.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-12-31¥5.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-12-31¥4.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-12-31¥3.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-12-31¥1.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-12-31−¥236m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥9.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥126m
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue2022-04-01 → 2022-12-31¥427.4bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue external2022-04-01 → 2022-12-31¥419.4bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segmentsegment profit2022-04-01 → 2022-12-31¥2.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥13.8bn
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥6m
jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥77m
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥283m
—segment totalrevenue2022-04-01 → 2022-12-31¥449.4bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥441.4bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥8.0bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥3.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥454.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥444.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥9.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 377
ItemContextValueUnit
Selling general and administrative expensesPrior1YTDDuration31977000000JPY
Selling general and administrative expensesCurrentYTDDuration30714000000JPY
Operating incomePrior1YTDDuration3061000000JPY
Operating incomeCurrentYTDDuration5658000000JPY
Interest income noiPrior1YTDDuration51000000JPY
Interest income noiCurrentYTDDuration50000000JPY
Dividends income noiPrior1YTDDuration555000000JPY
Dividends income noiCurrentYTDDuration492000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration83000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration21000000JPY
Other noiPrior1YTDDuration695000000JPY
Other noiCurrentYTDDuration439000000JPY
Non operating incomePrior1YTDDuration1385000000JPY
Non operating incomeCurrentYTDDuration1004000000JPY
Interest expenses noePrior1YTDDuration74000000JPY
Interest expenses noeCurrentYTDDuration74000000JPY
Rent expenses noePrior1YTDDuration60000000JPY
Rent expenses noeCurrentYTDDuration58000000JPY
Other noePrior1YTDDuration9000000JPY
Other noeCurrentYTDDuration23000000JPY
Non operating expensesPrior1YTDDuration144000000JPY
Non operating expensesCurrentYTDDuration156000000JPY
Ordinary incomePrior1YTDDuration4302000000JPY
Ordinary incomeCurrentYTDDuration6506000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration15000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration46000000JPY
Gain on sales of investment securities eiPrior1YTDDuration59000000JPY
Gain on sales of investment securities eiCurrentYTDDuration1221000000JPY
Other eiPrior1YTDDuration－JPY
Other eiCurrentYTDDuration26000000JPY
Extraordinary incomePrior1YTDDuration74000000JPY
Extraordinary incomeCurrentYTDDuration1295000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration0JPY
Loss on sales of noncurrent assets elCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration22000000JPY
Impairment loss elCurrentYTDDuration49000000JPY
Loss on sales of investment securities elPrior1YTDDuration26000000JPY
Loss on sales of investment securities elCurrentYTDDuration－JPY
Loss on valuation of investment securities elPrior1YTDDuration56000000JPY
Loss on valuation of investment securities elCurrentYTDDuration42000000JPY
Soil removal expenses elPrior1YTDDuration136000000JPY
Soil removal expenses elCurrentYTDDuration－JPY
Dismantlement expense elPrior1YTDDuration－JPY
Dismantlement expense elCurrentYTDDuration47000000JPY
Other elPrior1YTDDuration2000000JPY
Other elCurrentYTDDuration36000000JPY
Extraordinary lossPrior1YTDDuration244000000JPY
Extraordinary lossCurrentYTDDuration176000000JPY
Income before income taxesPrior1YTDDuration4132000000JPY
Income before income taxesCurrentYTDDuration7625000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass